Pathogenic vaginal and urogenital bacteria

Pathogenic vaginal and urogenital bacteria represent a broad group of microorganisms responsible for various infections of the reproductive and urinary systems. This group includes organisms such as Gardnerella vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, and uropathogenic Escherichia coli. These pathogens often cause disease by displacing beneficial commensal species, such as Lactobacillus, or by invading mucosal tissues, leading to conditions like bacterial vaginosis, urethritis, and pelvic inflammatory disease [StatPearls: NBK459216, CDC STI Guidelines]. Treatment typically involves the use of antimicrobial agents that target specific bacterial structures or metabolic pathways, such as cell wall synthesis or protein translation [PubChem]. However, the emergence of antimicrobial resistance, particularly in species like N. gonorrhoeae, and the potential for recurrent infections due to biofilm formation present ongoing challenges in clinical practice [WHO, Nature Reviews Microbiology]. Effective management requires accurate diagnosis through biomarkers like vaginal pH and nucleic acid amplification tests to ensure targeted therapy and minimize disruption to the healthy microbiome.

Other names

Urogenital pathogensVaginal pathogensBacterial vaginosis-associated bacteriaBVABSexually transmitted infection agentsUropathogenic bacteria

Antibiotics targeting these bacteria act through various pathways: nitroimidazoles (e.g., metronidazole) cause DNA strand breakage; macrolides (e.g., azithromycin) and tetracyclines (e.g., doxycycline) inhibit protein synthesis by binding to ribosomal subunits; and beta-lactams (e.g., ceftriaxone) inhibit peptidoglycan cross-linking in the bacterial cell wall [PubChem, CDC].